Skip to main content

REGENERON PHARMACEUTICALS, INC.

corporate_fare Company Profile

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
REGN
Apr 10, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
REGN
Apr 08, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
REGN
Apr 02, 2026, 4:50 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
REGN
Apr 02, 2026, 12:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Mar 24, 2026, 2:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Mar 11, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
7
REGN
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
REGN
Feb 04, 2026, 9:08 AM EST
Filing Type: 10-K
Importance Score:
8
REGN
Jan 30, 2026, 6:51 AM EST
Filing Type: 8-K
Importance Score:
7
REGN
Jan 12, 2026, 6:48 AM EST
Filing Type: 8-K
Importance Score:
7